Lee Jason Joon Bock, Park Jun Su, Hong Hyun Pyo, Kim Myung Sub, Koo Dong-Hoe, Lee Hyebin, Nam Heerim
Department of Radiation Oncology, Kangbuk Samsung Hospital, Sungkyunkwan University School of Medicine, Seoul 03181, Republic of Korea.
Department of Radiation Oncology, Chungnam National University Sejong Hospital, Chungnam National University School of Medicine, Sejong 30099, Republic of Korea.
J Pers Med. 2023 Feb 17;13(2):354. doi: 10.3390/jpm13020354.
This study assessed the use of pretreatment albumin--bilirubin (ALBI) grade as a prognostic factor in patients with hepatocellular carcinoma (HCC) receiving combined transarterial chemoembolization (TACE) and radiotherapy (RT). Patients who underwent RT following TACE between January 2011 and December 2020 were analyzed retrospectively. The survival outcomes of patients in regard to the ALBI grade and Child-Pugh (C-P) classification were evaluated. A total of 73 patients with a median follow-up of 16.3 months were included. Thirty-three (45.2%) and forty patients (54.8%) were categorized into ALBI grades 1 and 2-3, respectively, while sixty-four (87.7%) and nine (12.3%) were C-P classes A and B, respectively ( = 0.003). The median progression-free survival (PFS) and overall survival (OS) for ALBI grade 1 vs. 2-3 were 8.6 months vs. 5.0 months ( = 0.016) and 27.0 months vs. 15.9 months ( = 0.006), respectively. The median PFS and OS for C-P class A vs. B were 6.3 months vs. 6.1 months ( = 0.265) and 24.8 months vs. 19.0 months ( = 0.630), respectively. A multivariate analysis showed that ALBI grades 2-3 were significantly associated with worse PFS ( = 0.035) and OS ( = 0.021). In conclusion, the ALBI grade could be a good prognosticator in HCC patients who were treated with combined TACE-RT.
本研究评估了治疗前白蛋白-胆红素（ALBI）分级作为接受经动脉化疗栓塞（TACE）联合放疗（RT）的肝细胞癌（HCC）患者预后因素的作用。对2011年1月至2020年12月期间接受TACE后再行RT的患者进行回顾性分析。评估了患者的生存结局与ALBI分级及Child-Pugh（C-P）分级的关系。共纳入73例患者，中位随访时间为16.3个月。分别有33例（45.2%）和40例（54.8%）患者被归类为ALBI 1级和2-3级，而分别有64例（87.7%）和9例（12.3%）患者为C-P A级和B级（P = 0.003）。ALBI 1级与2-3级患者的中位无进展生存期（PFS）分别为8.6个月和5.0个月（P = 0.016），中位总生存期（OS）分别为27.0个月和15.9个月（P = 0.006）。C-P A级与B级患者的中位PFS分别为6.3个月和6.1个月（P = 0.265），中位OS分别为24.8个月和19.0个月（P = 0.630）。多因素分析显示，ALBI 2-3级与较差的PFS（P = 0.035）和OS（P = 0.021）显著相关。总之，ALBI分级可能是接受TACE-RT联合治疗的HCC患者的良好预后指标。
